A Phase 1 Study of Talazoparib (BMN 673) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors
Latest Information Update: 31 Aug 2023
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Talazoparib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 26 Aug 2023 Status changed from active, no longer recruiting to completed.
- 22 Aug 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Dec 2019.
- 25 Jul 2019 Status changed from suspended to active, no longer recruiting.